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Calcium balance in chronic kidney disease is poorly
understood as calcium deficiency is a stimulus for secondary
hyperparathyroidism and consequent bone loss while
calcium excess promotes extraosseous calcifications. To help
resolve this, we evaluated calcium balance in normal
individuals and in patients with chronic kidney disease (CKD)
on daily diets containing 800 and 2000mg elemental
calcium. Both normal individuals and patients with late stage
3 and stage 4 CKD were in slightly negative to neutral
calcium balance on the 800-mg calcium diet. Normal
individuals were in modest positive calcium balance on the
2000-mg diet, while patients with CKD on the same diet
were in marked positive calcium balance at least over the
9 days of study; and significantly greater than the normal
individuals. Increased calcium intake significantly decreased
1,25-dihydroxy-vitamin D and intact parathyroid hormone
levels but did not alter the serum calcium concentration.
Thus, our findings have important implications for both
preventing calcium deficiency and loading in individuals with
late stage 3 and stage 4 CKD.
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Serum calcium concentrations are maintained in the normal
range until very late in chronic kidney disease (CKD) when it
decreases slightly.1,2 However, calcium balance in CKD is
poorly understood. Gastrointestinal (GI) calcium absorption
has been shown to be lower in CKD subjects on normal
calcium intake than in controls, and yet remains dependent
on calcium intake.3 It is generally believed that decreased
levels of circulating 1,25-dihydroxy-vitamin D (1,25-D), the
principal hormone regulating transcellular calcium absorp-
tion in the GI tract,4 results in decreased calcium absorption
and net negative calcium balance, providing a stimulus for
secondary hyperparathyroidism early in CKD. Late in CKD,
serum calcium concentrations decrease, as circulating 1,25-D
continues to decrease, thus providing support to this
hypothesis. The decreasing 1,25-D concentrations coupled
with a decrease in serum calcium concentrations late in CKD
suggest that CKD patients may be in net negative calcium
balance and that calcium supplementation may be needed to
correct the calcium absorption defect.
To date, there are no adequate calcium balance studies in
CKD. In normal adults, calcium balance is relatively neutral
when calcium intake ranges between 750 and 1740mg/day,
although significant individual variability exists.5 Twenty-
four-hour urinary calcium excretion generally ranges be-
tween 100 and 300mg/day, largely reflecting dietary intake
with a fractional GI absorption between 10 and 60%
depending on 1,25-D concentrations and calcium intake.6,7
However, studies that have measured 24-h urinary calcium
excretion in patients with advanced CKD consistently show
low 24 h excretion, usually o80mg/day.8,9 Even CKD
patients on escalating doses of calcium-based phosphate
binders consistently had low urinary calcium excretion often
in the range of 20–60mg/day.10
Understanding calcium balance is particularly important
in CKD, as it is characterized by a high prevalence of vascular
calcification, which is associated with cardiovascular and all-
cause mortality.11 Although vascular calcification is thought
to result from a complex disruption of normal vascular
biology,12 there is ongoing controversy whether supplemental
calcium accelerates this process both in CKD and in dialysis
patients.13 Furthermore, the increasing concern over phos-
phorus balance early in CKD and the observational finding
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that CKD nondialysis patients treated with phosphate binder
have improved survival14 may increase the use of calcium-
containing phosphate binders in CKD despite the lack of
long-term safety data.
Therefore, the purpose of this study was to formally
evaluate calcium balance in late stage 3 and stage 4 CKD
compared with control subjects. We hypothesized that
subjects with advanced CKD are in positive calcium balance
on high dietary calcium intake, and that this positive balance
is not reflected in the serum calcium concentration, which is
tightly regulated. If true, this hypothesis would suggest that
exposure to high calcium intake results in positive calcium
balance in CKD, leading to calcium loading, which may
precipitate or worsen vascular and soft-tissue calcification.
RESULTS
The study timeline is shown in Figure 1. Six subjects with
advanced stage 3 or stage 4 CKD and six control subjects
completed both diet arms. One control subject was dropped
from the study because of inability to eat the prescribed diet
during the first diet period, and was not included in the data
analysis. Two other control subjects were consented, but they
failed vitamin D screening or withdrew consent and never
started the active diet phase. One CKD subject had an inter-
diet collection period that exceeded the study protocol by
several months because of an intercurrent illness.
All subjects did a good job with the diets eating only, and
most of the food prepared. The average calcium and
phosphorus intake for subjects during their 48-h inpatient
diet periods were as follows: CKD—low-calcium diet:
calcium (Ca) 812±4, phosphorus (phos) 1575±59; high-
calcium diet: Ca 2009±9, phos 1672±62; control—low
calcium diet: Ca 787±42, phos 1518±136; high-calcium
diet: Ca 1903±160, phos 1545±125mg/day. Serum calcium
concentrations were not different between CKD and control
subjects on either diet, and there was no intra-patient
difference between the 800- and 2000-mg calcium diets
(Figure 2a). Serum phosphorus was significantly higher in
CKD subjects on the 800-mg calcium diet (4.15±0.20 vs.
3.56±0.09mg/dl, P¼ 0.02) and trended higher on the 2000-
mg calcium diet (4.06±0.20 vs. 3.63±0.11mg/dl, P¼ 0.10),
but again did not show an intra-patient difference between
the low- and high-calcium diets (Figure 2b). However, in
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Figure 1 | Timeline of study interventions. CTRC, clinical trials research center.
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Figure 2 | Serum calcium (Ca) and phosphorus in control and
chronic kidney disease (CKD) subjects on 800- and 2000-mg
Ca diets. Serum Ca (a) and phosphorus (b) on 800- and 2000-mg
Ca diets. Filled circles, CKD subjects; filled triangles, controls.
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response to the increase calcium in the diet, both the serum
1,25-D and the immunoreactive parathyroid hormone
(iPTH) decreased significantly when subjects were on the
2000-mg calcium diet compared with the 800-mg calcium
diet (Table 1, Figure 3). 25-D levels were lower in CKD
subjects than in controls (33.4±1.9 vs. 43.2±1.8 ng/ml,
P¼ 0.001), but did not change between diets in either group.
Total urinary phosphorus excretion was not different
between CKD and controls and did not vary by calcium
diet (Table 2, Figure 4a). However, the tubular reabsorption
of phosphorus was significantly lower in CKD than in
controls (62.4±12.8 vs. 85.4±2.2, P¼ 0.002) and fit closely
with the logarithmic exponent as previously reported15
(Figure 4b).
Although some patients demonstrated an increase in
urinary calcium on higher calcium intake (Table 2), the
intra-patient urinary calcium excretion was not different for
CKD or control groups. However, the urinary calcium
excretion was significantly lower in CKD subjects compared
with controls on both the 800- (83.0±47.6 vs. 272.1±103.6,
Po0.05) and 2000-mg (99.0±71.7 vs. 333.9±166.3,
Po0.05) calcium diets (Table 2, Figure 5a). The stool
calcium/phosphorus ratio was slightly, although not sig-
nificantly, lower in controls vs. CKD subjects on the 800-mg
calcium diet, possibly suggesting greater calcium absorption
in controls, consistent with the higher 1,25-D concentrations
(Figure 5b). On the 2000-mg calcium diet, both control and
CKD subjects demonstrated an increase in stool calcium/
phosphorus compared with the 800-mg calcium diet as
expected, although this was slightly greater and only
statistically significant in the control group. There was no
difference in the stool calcium phosphorus ratio between
groups on either diet (Figure 5b). The fact that CKD subjects
did not increase their stool calcium/phosphorus ratio more
than controls strongly suggests that marked downregulation
or impairment of GI calcium absorption is not occurring in
CKD and cannot account for the low urinary calcium
excretion in this group. The estimated percent of ingested
dietary calcium absorbed increased from 5±21 to 47±10%
in CKD subjects and from 16±26 to 41±11% in controls on
the 800- and 2000-mg calcium diets, respectively. Estimated
calcium balance was slightly negative in CKD subjects on the
800-mg calcium intake (although the 95% confidence interval
crossed the neutral line), but markedly positive on the 2000-mg
calcium intake (Table 2, Figure 6). Control subjects were also
in slightly negative calcium balance on the 800-mg calcium
diet, but again this was not statistically significant. Control
subjects were also in positive calcium balance on the 2000-mg
Table 1 | Baseline information and 1,25-D and iPTH concentrations by diet
800-mg calcium diet 2000-mg calcium diet
Age (years) Gender
Creatinine
(mg/dl)
eGFR (MDRD-4),
ml/min per 1.73m2 1,25-D (pg/ml) iPTH (pg/ml) 1,25-D (pg/ml) iPTH (pg/ml)
CKD-1 51 M 4.1 20 26.5 369.5 26.5 330.0
CKD-2 56 F 1.6 33 24.0 149.5 24.5 64.5
CKD-3 64 M 2.5 23 32.5 102.5 25.0 79.5
CKD-4 62 M 2.5 25 27.0 255.0 24.0 260.5
CKD-5 73 M 1.8 31 25.5 106.5 13.5 82.0
CKD-6 70 M 2.1 32 31.0 353.0 21.5 246.5
Cont-1 47 F 0.8 82 32.5 53.1 28.0 39.7
Cont-2 40 F 0.7 99 70.5 37.6 59.0 30.3
Cont-3 36 F 0.8 86 97.5 33.8 75.5 34.7
Cont-4 67 F 0.7 89 39.5 57.5 28.0 59.5
Cont-5 45 M 1.3 66 31.5 41.3 33.5 29.8
Cont-6 52 M 1.2 71 33.0 26.9 31.5 27.4
Abbreviations: CKD, chronic kidney disease; Cont, control; eGFR, estimated glomerular filtration rate; F, female; iPTH, immunoreactive parathyroid hormone; M, male; MDRD,
Modification of Diet in Renal Disease; 1,25-D, 1,25-dihydroxy-vitamin D.
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Figure 3 | Serum 1,25-dihydroxy-vitamin D and
immunoreactive parathyroid hormone (iPTH) in control
and chronic kidney disease (CKD) subjects on 800- and
2000-mg calcium (Ca) diets. Serum 1,25-dihydroxy-vitamin D
(1,25-D, a) and iPTH (b) on 800- and 2000-mg Ca diets. Filled
circles, CKD subjects; filled triangles, controls.
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calcium diets, although significantly less positive than CKD
subjects (Table 2, Figure 6).
DISCUSSION
This is the first study to evaluate calcium balance in advanced
CKD. We found that subjects with late stage 3 and stage 4
CKD were in slightly negative to neutral calcium balance on a
daily intake of 800mg, but were in marked positive balance
on 2000mg/day. This finding is in agreement with modeled
balance data in dialysis patients, predicting negative balance
when intake is o800 and positive balance when calcium
intake exceeds 1500mg/day.16 Our finding of low urinary
calcium excretion in CKD is in agreement with previously
reported 24-h urine calcium excretion in subjects with
CKD.8,9 The finding that urinary calcium did not increase in
CKD subjects on the high-calcium diet while the stool
calcium to phosphorus ratio did not differ from controls
supports our finding of marked positive calcium balance in
the CKD subjects on the high-calcium diet and suggests that
significant downregulation or impairment of GI calcium
absorption is not occurring in CKD. Together, these findings
demonstrate that CKD patients receiving 2000mg of
elemental calcium have a substantial increase in calcium
absorption, resulting in positive balance without escape over
the time period studied. The finding that 1,25-D and iPTH
concentrations decreased on the high-calcium diet supports
the finding that increasing calcium absorption is down-
regulating these hormones. However, despite the decrease in
1,25-D, net calcium absorption increased on the high-
calcium diet, possibly related to absorption via the less
regulated, non-saturable paracellular pathway.4 The finding
that the dietary calcium absorption was slightly lower in CKD
subjects on the low-calcium diet than controls is consistent
with the lower 1,25-D levels, the principal hormone
regulating transcellular calcium absorption in the GI tract
when dietary calcium is low. On high calcium intake, GI
calcium absorption increased significantly in both groups as
previously reported.17 The percent calcium absorption in this
study was quite variable between patients but consistent with
early studies reporting absorption between 26 and 63% on
800mg/day and between 18 and 30% on 2000mg/day.17
Table 2 | Urine and stool calcium and phosphorus and net balance
800-mg Ca 2000-mg Ca
800-mg Ca 2000-mg Ca
Estimated Ca balance
Diets Urine Ca Urine P Urine Ca Urine P Stool Ca/P ratio Stool Ca/P ratio 800-mg Ca 2000-mg Ca
CKD-1 165 1117 244 937 1.02 1.16 153 975
CKD-2 49 919 52 1032 1.43 1.89 208 908
CKD-3 78 1097 78 1064 1.39 1.55 27 959
CKD-4 112 871 73 851 1.12 1.60 130 542
CKD-5 55 917 63 1025 1.63 1.79 143 812
CKD-6 40 1001 85 1036 1.19 1.54 80 821
Mean±s.d. 83±48 987±102 99±72 991±81 1.30±0.23 1.59±0.25 91±113 759±120
Cont-1 245 925 190 1121 1.43 1.98 432 761
Cont-2 411 710 349 723 0.98 1.59 239 184
Cont-3 227 955 591 1015 1.13 1.96 117 307
Cont-4 231 890 304 869 1.01 1.69 74 501
Cont-5 137 820 134 675 0.97 1.41 79 565
Cont-6 380 1246 435 1504a 1.13 1.90 79 1342a
Mean±s.d. 272±104 925±180 334±166 881±189 1.11±0.17 1.76±0.23 144±174 464±225
Abbreviations: Ca, calcium; CKD, chronic kidney disease; Cont, control; P, phosphorus.
aIndicates data not used in statistical analysis, as this urinary phosphorus would require 94% of the dietary phosphorus to have been absorbed. All other urine and stool
parameters are within expected ranges.
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Figure 4 |Twenty-four-hour urinary phosphorus (Phos)
excretion on 800- and 2000-mg calcium (Ca) diets and tubular
reabsorption of phosphorus by estimated glomerular
filtration rate (eGFR) in control and chronic kidney disease
(CKD) subjects. Twenty-four-hour Phos excretion (a) and tubular
reabsorption of phosphorus (b). Filled circles, CKD subjects;
filled triangles, controls.
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Control subjects were in slightly negative balance to neutral
calcium balance on the low-calcium diet and in positive
balance on the 2000mg/day calcium diet, although not as
positive as CKD subjects. The observation that the serum
calcium concentrations did not change in either group is
consistent with the knowledge that the serum calcium
concentration is tightly regulated17 and suggests that calcium
loading occurs when CKD and possibly control subjects are
exposed to high calcium intake. This is consistent with
studies in pediatric patients with CKD showing vascular
calcium loading in children with advanced CKD.18
There are a number of limitations in this study. The sample
size was small. However, the study was tightly controlled and
the findings are consistent across subjects. Because of
inaccuracies in the stool dye technique, we were unable to
measure a true 24-h stool sample. Although a stable calcium
isotope could be used to measure GI calcium absorption, the
method is expensive. We therefore chose to estimate the 24-h
stool production by assuming that patients were in neutral
phosphorus balance, and normalizing the stool calcium to
24 h based on these calculations. Although this was an
assumption we could not test, previous research suggests that
it is correct.15,19 Furthermore, if this was incorrect and CKD
subjects were in positive phosphorous balance rather than
neutral phosphorus balance, this would only serve to increase
their net calcium balance. If CKD subjects were in negative
phosphorus balance (due to continued urinary losses in the
face of decreased absorption from calcium binding), then our
results would overestimate net calcium balance. However,
even a 20 or 40% overestimation would still place the CKD
subjects in net positive calcium balance. It is possible that
both control and CKD subjects may have been accruing bone
mass when on the high-calcium diet. It is also possible that
the 7 days of diet equilibration was not long enough for
subjects to return to a steady state, especially on the high-
calcium diet, and given more time control subjects may have
been able to increase their urinary calcium excretion to
achieve balance. There is currently very little literature to
define a time course for return to steady state following
changes in dietary calcium. However, it has been shown that
following a decrease in dietary calcium intake from 2000mg
to 300mg/day, urinary calcium nadirs by week 1 and the
counter-regulatory hormones, parathyroid hormone and
1,25-D, reach a maximum at 1 week.20 In general, renal
conservation of a filtered substance takes longer than
decreased reabsorption, suggesting that 7 days may be
adequate, although we cannot be certain that our control or
CKD subjects were in a true steady state. It is also possible that
CKD subjects may require a longer time period than controls
to reestablish balance. However, a long-term study (6 weeks)
following urinary calcium excretion in CKD subjects treated
with increasing dosage of calcium-based binders failed to
show a significant increase in urinary calcium excretion,
suggesting that even after 6 weeks CKD subjects fail to
increase their urinary calcium excretion in response to
increased calcium intake.10 Finally, although this study
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Figure 5 | Twenty-four-hour urinary calcium (Ca) excretion and
stool Ca to phosphorus ratio in control and chronic kidney
disease (CKD) subjects on 800- and 2000-mg Ca diets. Twenty-
four-hour urinary Ca excretion (a) and stool Ca/phosphorus (Phos)
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strongly suggests that CKD subjects on a high-calcium diet
are in positive calcium balance, we cannot be certain that this
calcium is being deposited in soft tissue. It is possible that
bone buffering could be occurring over the time period
studied. However, it is unlikely that the bones could
continually accumulate calcium in CKD subjects if positive
calcium balance was maintained over weeks to months as
might occur with long-term high calcium intake.
In summary, this study found that subjects with advance
stage 3 or stage 4 CKD are in slightly negative balance to
neutral calcium balance on 800mg calcium intake but in
marked positive balance when ingesting 2000mg of elemental
calcium. The increased calcium load when moving from an
800- to a 2000-mg calcium intake resulted in lower 1,25D and
iPTH but did not result in overall net decreased calcium
absorption or an increase in the serum calcium concentration,
suggesting that the calcium is being deposited in tissue. This
finding is consistent with what is known regarding sodium
and water balance in CKD where flexibility in urinary
excretion is lost and dietary intake needs to be adjusted for
patients to remain in balance. If confirmed in larger balance
studies, these findings suggest that elemental calcium intake
should be limited to 800–1200mg in individuals with late
stage 3 or stage 4 CKD who are not on active vitamin D
analogs, and possibly to 800–1000mg in subjects receiving
active vitamin D (although this was not studied in this trial).
Finally, this study underscores the fact that the serum calcium
cannot be used as a guide to evaluate calcium balance, and
normal serum calcium concentrations do not preclude
calcium loading. This study suggests that knowledge of
dietary calcium intake and the use of active vitamin D need to
be considered when calcium is prescribed to patients with
CKD. Furthermore, in adults with CKD, total elemental
calcium intake should be within 800–1200mg/day to prevent
calcium deficiency and calcium loading. These values are close
to the current estimated average requirement (800–1000mg/
day) and the recommended dietary allowance (1000–1200mg/
day—amount needed to meet or exceed the requirement of
97.5% of healthy adults) in the recent Institute of Medicine
Report on dietary reference intakes for calcium.21
MATERIALS AND METHODS
This study used a crossover designed to evaluate calcium balance on
an 800-mg elemental calcium per day diet vs. a 2000mg/day diet in
late stage 3 and stage 4 CKD subjects vs. controls with normal
kidney function. Subjects were required to complete both study
periods for inclusion in the data analysis.
Following informed consent, a screening 25-D level was measured.
If the level waso30ng/ml, subjects were supplemented with vitamin
D (ergocalciferol 50,000 IU weekly) and rescreened at 4 weeks. If the
25-D level was still o30ng/ml, subjects could undergo a second
supplementation period followed by rescreening. If the 25-D level was
still o30ng/ml, subjects were excluded. No subjects were receiving
any bone modifying medications, and all subjects were instructed to
discontinue all calcium supplements and any vitamins or antacids
containing calcium at least 1 month before study entry. Subjects who
passed the 25-D screening were assigned to the calcium diets in
random order. Diet 1: 800mg elemental calcium and 1600mg
phosphorus; Diet 2: 2000mg elemental calcium and 1600mg
phosphorus. Each diet phase was a total of 9 days, the first 7 as an
outpatient. For each active diet phase, subjects were supplied with all
outpatient meals and snacks prepared by the clinical trials research
center dietary facilities at the University of Colorado. Subjects were
instructed to eat only food and non-water drinks provided, but could
drink water ad lib. Subjects were instructed to return any uneaten
food. Following this outpatient phase, subjects were admitted to the
clinical trials research center for 48h. The experimental diet was
continued during this stay and subjects were given deionized water
ad lib. During the inpatient stay, each subject had two 24-h urine
collections for calcium, phosphorus, and creatinine, and fasting
morning labs for creatinine, calcium, phosphorus, 25-D, 1,25-D, and
iPTH. During this time period, all stool samples were collected and
frozen and sent to Covance Laboratory (Madison, WI) for
measurement of calcium and phosphorus content for determination
of 24-h stool calcium excretion (see below). Any patient who could
pass stool only once during the 48-h stay was asked to collect the next
sample at home in an iced container. All but one control subject had
at least two stool samples used in the analysis.
Following the first inpatient stay, subjects resumed their normal
diet for a period of at least 1 week, but up to 4 weeks before initiating
the second diet phase. During the entire study period, subjects
continued to receive vitamin D supplementation, either their routine
home vitamin or ergocalciferol 50,000 IU, every month.
Serum and urine calcium, phosphorus, and urine creatinine were
measured in the University of Colorado clinical laboratory. Serum
creatinine, 25-D, 1,25-D, and iPTH were measured in the Denver
Children’s Hospital clinical laboratory. The tubular reabsorption
of phosphorus was calculated from the 24-h urine collections and
the fasting phosphorus by using the following equation: 1((Uphos/
serum phos) (serum creat/Ucreat) 100).
Stool calcium and phosphorus quantification
All stool samples collected for each subject were combined, weighed,
dried, precharred, and ashed overnight in a muffle set to maintain a
temperature of 5001C. The ashed sample was re-ashed with nitric
acid, treated with hydrochloric acid, taken to dryness, and added
into a solution of 5% hydrochloric acid. The amount of calcium and
phosphorus was determined at appropriate wavelengths by compar-
ing the emission of the unknown sample, measured on the
inductively coupled plasma spectrometer, with the emission of the
standard solutions. The stool calcium/phosphorus ratio was
calculated as the total stool calcium divided by the total stool
phosphorus. The initial plan for the calculation of the 24-h stool
calcium excretion was to perform a double-labeled stool collection
by administration of brilliant blue (100mg) 24 h before clinical trials
research center admission and at the midpoint of the hospital stay.
Stool collected between the two blue-stained stool samples was to be
collected and analyzed and would represent 48 h of stool. However,
because of marked inaccuracy and variation with GI transit time,
dye streaking, and sometimes no clear dye-free stool, this method it
was not used for the study. Instead, 24-h stool excretion was
estimated as follows. It was assumed that both CKD and control
subjects were in neutral phosphorus balance. This assumption is in
agreement with published findings15,19 and supported by the finding
that all subjects (both CKD and control) excreted equal amounts of
phosphorus in the urine during both diet phases. Although dietary
calcium and, to a lesser extent, 1,25-D concentrations are known to
exert modulating effects on GI phosphate absorption, based on the
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fixed and equal phosphorus content of both diets and equal urinary
phosphorus excretion, we felt that the assumption that all patients
were in phosphorus balance was reasonable. Therefore, the phos-
phorus intake minus the urinary phosphorus excretion allowed for a
close estimate of the expected 24-h stool phosphorus. The total stool
phosphorus content was then divided by the expected 24-h stool
phosphorus to determine the time period of the stool analyzed. The
total stool calcium was then divided by this time factor to determine
the 24-h stool calcium content for each subject for each diet phase.
For example, the expected 24-h stool phosphorus for a subject with
900mg of urinary phosphorus would be calculated as intake
(1600mg) minus the 24-h urine phosphorus (900mg)¼ 700mg.
The actual total stool phosphorus content measured (e.g., 1100mg)
was divided by 700mg to determine the number of days the total
collected stool represented. In this example, 1100/700¼ 1.57 days.
The total measured stool calcium was then divided by this number to
estimate the 24-h stool calcium excretion.
Balance calculations
Although calcium is known to be secreted into the GI tract and small
amounts are lost in sweat,22 this study used the simplified definition
of balance previously reported5 as Balance¼ oral intakeurine
outputstool output. As the serum calcium concentrations did not
change significantly on either diet, it was not felt that the small
changes observed needed to be included in the balance equation.
Statistical analysis
Differences within groups between diets were analyzed by the paired
t-test. Differences between groups were analyzed by the non-paired
t-test for two groups or one-way analysis of variance with Tukey
post-test for multiple comparisons. Analyses were performed with
GraphPad Prism version 5.0 (San Diego, CA). A P-valueo0.05 was
considered statistically significant.
This study was conducted in accordance with the ethical
standards of the responsible committee on human experimentation,
and was approved by the Institutional Review Boards of the
University of Colorado #070959. The trial is registered with
ClinicalTrials.gov, Identifier: NCT00974532.
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